JPRN-UMIN000007863
Completed
未知
A second phase study for the cancer pain: Drug Rotation from Oral Opioid to Daily type Transdermal Fentanyl tape. - PROOF study
ISESAKI MUNICIPAL HOSPITA0 sites20 target enrollmentMay 1, 2012
Conditionscancer pain
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- cancer pain
- Sponsor
- ISESAKI MUNICIPAL HOSPITA
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients with serious hepatic, renal, heart or respiratory dysfunctions 2\. Patients with medical history of psychiatry disease 3\. Pregnant or nursing patients and patients who may be pregnant 4\. Patients with disturbed consciousness 5\. Contraindication to opioid 6\. Patients who has received narcotic antagonist analgesic 7\. Patients who is evaluated as in appropriate for this study by investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Study with cancer patients followed at the Cecon Foundation Pain Therapy and Palliative Care Service to analyze whether a Meditation intervention using Virtual Reality glasses will alleviate Pain and improve patients' quality of lifeQuality of lifeMeditationVirtual RealityPalliative MedicineF04.754.539RBR-77sqd4zFundação Centro de Controle de Oncologia do Estado do Amazonas - FCECO
Recruiting
Not Applicable
Objective evaluation of cancer pain using non-contact sensorJPRN-UMIN000035330Tottori University Faculty of Medicine40
Completed
Not Applicable
Anti-tumor efficacy of TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy Using BALF, Plasma or Pleural EffusioNeoplasmsKCT0003232Asan Medical Center63
Active, not recruiting
Phase 1
A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant Tumorslocally advanced (primary or recurrent) or metastatic solid tumors with a pathogenic or likely pathogenic germline or loss-of-function somatic BRCA1, or BRCA2, or ATM gene defectMedDRA version: 20.0 Level: LLT Classification code 10065147 Term: Malignant solid tumor System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-000345-39-NLPfizer Inc., 235 East 42nd Street, New York, NY 10017541
Completed
Phase 2
A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant TumorsNL-OMON48840Pfizer22